Pfizer compiling data to answer DCGI queries on coronavirus vaccine

Drug major clarifies it could not present itself before the SEC because of short notice and time zone issues

After a three-time no-show before the expert panel on vaccines in India, US major Pfizer, which was one of the first firms to apply for a restricted emergency use approval here, says it is compiling responses to queries raised by the Indian regulator.

The company spokesperson clarified that the firm is committed to engaging with the Government of India.

A Pfizer spokesperson elaborated: “Pfizer sought an opportunity to participate in the Subject Expert Committee (SEC) consultations towards an emergency use authorisation for our Covid-19 vaccine. However, the company representatives have been unable to participate in previous meetings because of extremely short notices